Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: Involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway

International Journal of Oncology

Volumn 49, Issue 5, 2016, Pages 2075-2087

  Cao, Shijie ^a,b   Xia, Meijuan ^a   Mao, Yiwei ^a,b   Zhang, Qiang ^b   Donkor, Paul Owusu ^b   Qiu, Feng ^a,b   Kang, Ning ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cetuximab; Epidermal growth factor receptor; Laryngeal squamous cell carcinoma; Oridonin; ROS mediated JNK pathway; Synergistic anticancer effects

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ANTIGEN; ORIDONIN; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; KAURANE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HEP 2 CELL LINE; HUMAN; HUMAN CELL; LARYNX SQUAMOUS CELL CARCINOMA; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA CELL LINE; TU212 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; LARYNGEAL NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CETUXIMAB; DITERPENES, KAURANE; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; LARYNGEAL NEOPLASMS; MAP KINASE KINASE 4; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84992663705     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3696     Document Type: Article

References (52)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
3. Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. N Engl J Med 345: 1890-1900, 2001.
4. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW and Burgess AW: Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 284: 31-53, 2003.
5. Rocha-Lima CM, Soares HP, Raez LE and Singal R: EGFR targeting of solid tumors. Cancer Control 14: 295-304, 2007.
6. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S and Nagura H: Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 74: 795-804, 1994.
7. Li FC, Li YH, Zhao X, Fu WN, Xu ZM, Li ZG and Sun KL: Association of homozygous deletion of p15 and p16 gene and amplification of EGFR gene in laryngeal squamous cell carcinoma. Yi Chuan Xue Bao 31: 109-113, 2004 (in Chinese).
8. Li F, Kang N, Fu W, Sun X, Gao H and Sun K: Detection of epidermal growth factor receptor gene amplification in human laryngeal carcinomas by means of fluorescence in situ hybridization. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 17: 278-280, 2000 (in Chinese).
9. Moghal N and Sternberg PW: Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol 11: 190-196, 1999.
10. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI and Goldstein NI: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 19: 419-427, 1996.
11. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, et al: Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. Clin Cancer Res 10: 6487-6501, 2004.
12. Huether A, Höpfner M, Baradari V, Schuppan D and Scherübl H: EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 70: 1568-1578, 2005.
13. Galizia G, Lieto E, De Vita F, Orditura M, Castellano P, Troiani T, Imperatore V and Ciardiello F: Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 26: 3654-3660, 2007.
14. K ohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, et al: Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 124: 2668-2682, 2014.
15. Le Tourneau C and Siu LL: Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 20: 256-263, 2008.
16. Wang R, Chen P, Fan QX and Wang R: Clinical efficacy for the treatment of esophageal cancer with rabdosia rubescens alone and combining with chemotherapy. Life Sci J 4: 22-25, 2007.
17. Wang R and Wang L: Efficacy of Rabdosia rubescens in treating 95 cases with esophageal and gastric cardiac cancer. Cancer Res Prev Treat 11: 86-87, 1994.
18. Kuo LM, Kuo CY, Lin CY, Hung MF, Shen JJ and Hwang TL: Intracellular glutathione depletion by oridonin leads to apoptosis in hepatic stellate cells. Molecules 19: 3327-3344, 2014.
19. Li X, Li X, Wang J, Ye Z and Li JC: Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int J Biol Sci 8: 901-912, 2012.
20. Zhang CL, Wu LJ, Tashiro S, Onodera S and Ikejima T: Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation, dependent on the cytochrome c/caspase-9 apoptosome. J Asian Nat Prod Res 6: 127-138, 2004.
21. Zhou GB, Chen SJ, Wang ZY and Chen Z: Back to the future of oridonin: Again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. Cell Res 17: 274-276, 2007.
22. Kang N, Zhang JH, Qiu F, Tashiro S, Onodera S and Ikejima T: Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett 294: 147-158, 2010.
23. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
24. Wang XJ, Li Y, Luo L, Wang H, Chi Z, Xin A, Li X, Wu J and Tang X: Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs. Free Radic Biol Med 70: 68-77, 2014.
25. Wang DT, He J, Wu M, Li SM, Gao Q and Zeng QP: Artemisinin mimics calorie restriction to trigger mitochondrial biogenesis and compromise telomere shortening in mice. PeerJ 3: e822, 2015.
26. Siegelin MD, Plescia J, Raskett CM, Gilbert CA, Ross AH and Altieri DC: Networks for therapy of glioblastoma global targeting of subcellular heat shock. Mol Cancer Ther 9: 1638-1646, 2010.
27. Yang D, Torres CM, Bardhan K, Zimmerman M, McGaha TL and Liu K: Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. J Immunol 188: 4441-4449, 2012.
28. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.
29. Lee WY, Liu KW and Yeung JH: Reactive oxygen speciesmediated kinase activation by dihydrotanshinone in tanshinones-induced apoptosis in HepG2 cells. Cancer Lett 285: 46-57, 2009.
30. Salcher S, Hagenbuchner J, Geiger K, Seiter MA, Rainer J, Kofler R, Hermann M, Kiechl-Kohlendorfer U, Ausserlechner MJ and Obexer P: C10ORF10/DEPP, a transcriptional target of FOXO3, regulates ROS-sensitivity in human neuroblastoma. Mol Cancer 13: 224, 2014.
31. Moon DO, Kim MO, Kang CH, Lee JD, Choi YH and Kim GY: JNK inhibitor SP600125 promotes the formation of polymerized tubulin, leading to G2/M phase arrest, endoreduplication, and delayed apoptosis. Exp Mol Med 41: 665-677, 2009.
32. Ciardiello F and Tortora G: A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958-2970, 2001.
33. Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P and Allal C: In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol 57: 709-718, 2006.
34. Park SJ, Kim MJ, Kim YK, Kim SM, Park JY and Myoung H: Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma. Cancer Lett 292: 54-63, 2010.
35. Zhang L, Li XF, Tand L, Zhao YM and Zhou CC: The effects of cetuximab in combination with docetaxel for the acquired resistance to EGFR-TKI in non-small cell lung cancer cells. Tumor 34: 584-590, 2014.
36. Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, Panahandeh MC, Hahm ER, Joyce SC, Sen M, et al: Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis 30: 1848-1856, 2009.
37. Wang YY, Lv YF, Lu L and Cai L: Oridonin inhibits mTOR signaling and the growth of lung cancer tumors. Anticancer Drugs 25: 1192-1200, 2014.
38. Bao R, Shu Y, Wu X, Weng H, Ding Q, Cao Y, Li M, Mu J, Wu W, Ding Q, et al: Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer 14: 217, 2014.
39. Li D, Wu LJ, Tashiro S, Onodera S and Ikejima T: Oridonin inhibited the tyrosine kinase activity and induced apoptosis in human epidermoid carcinoma A431 cells. Biol Pharm Bull 30: 254-260, 2007.
40. Xiao X, He Z, Cao W, Cai F, Zhang L, Huang Q, Fan C, Duan C, Wang X, Wang J, et al: Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways. Int J Oncol 48: 2608-2618, 2016.
41. Selvendiran K, Bratasz A, Tong L, Ignarro LJ and Kuppusamy P: NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatinresistant human ovarian cancer cells and xenografts. Cell Cycle 7: 81-88, 2008.
42. Iwase M, Takaoka S, Uchida M, Yoshiba S, Kondo G, Watanabe H, Ohashi M and Nagumo M: Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells. Oral Oncol 44: 361-368, 2008.
43. Kriegs M, Gurtner K, Can Y, Brammer I, Rieckmann T, Oertel R, Wysocki M, Dorniok F, Gal A, Grob TJ, et al: Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. Radiother Oncol 115: 120-127, 2015.
44. Kang N, Zhang JH, Qiu F, Chen S, Tashiro S, Onodera S and Ikejima T: Induction of G2/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells. J Nat Prod 73: 1058-1063, 2010.
45. Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo ZY, Xu MH, Wang ST, Jiang B, Liu F, et al: Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 10: 610, 2010.
46. Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM: Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun 337: 224-231, 2005.
47. Tandon M, Salamoun JM, Carder EJ, Farber E, Xu S, Deng F, Tang H, Wipf P and Wang QJ: SD-208, a novel protein kinase D inhibitor, blocks prostate cancer cell proliferation and tumor growth in vivo by inducing G2/M cell cycle arrest. PLoS One 10: e0119346, 2015.
48. Clerkin JS, Naughton R, Quiney C and Cotter TG: Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Lett 266: 30-36, 2008.
49. Cheng Y, Qiu F, Ye YC, Guo ZM, Tashiro S, Onodera S and Ikejima T: Autophagy inhibits reactive oxygen species-mediated apoptosis via activating p38-nuclear factor-kappa B survival pathways in oridonin-treated murine fibrosarcoma L929 cells. FEBS J 276: 1291-1306, 2009.
50. Li JP, Yang YX, Liu QL, Pan ST, He ZX, Zhang X, Yang T, Chen XW, Wang D, Qiu JX, et al: The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Drug Des Devel Ther 9: 1627-1652, 2015.
51. Sánchez-Pérez I, Martínez-Gomariz M, Williams D, Keyse SM and Perona R: CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 19: 5142-5152, 2000.
52. Pereira L, Igea A, Canovas B, Dolado I and Nebreda AR: Inhibition of p38 MAPK sensitizes tumour cells to cisplatininduced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med 5: 1759-1774, 2013.